UPDATE: JPMorgan Starts HilleVax, Inc. (HLVX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
UPDATE: Stifel Starts HilleVax, Inc. (HLVX) at Buy
May 24, 2022 3:36 AM EDT(Updated - May 24, 2022 5:16 AM EDT)
Stifel analyst Stephen Willey initiates coverage on HilleVax, Inc. (NASDAQ: HLVX) with a Buy rating and a price target of $34.00.
The analyst comments "We believe the burden of disease and direct/indirect healthcare costs associated with norovirus-caused AGE which disproportionately impacts young children (... More



